Immunology Licensing Deal Calculator —
benchmark your deal in 60 seconds
Phase 2 immunology deals median ~$80M upfront, ~$1B total. TL1A space has seen $1.2B+ upfront on lead assets. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.
Immunology deal benchmarks at a glance
Median deal terms for immunology licensing transactions, by development phase. Data current as of 2026.
| Phase | Median Upfront | Median Total Value | Median Royalty (Tiered) |
|---|---|---|---|
| Preclinical | $45M | $650M | 5–10% |
| Phase 1 | $100M | $950M | 8–14% |
| Phase 2 | $350M | $1.8B | 12–20% |
| Phase 3 | $440M | $2.2B | 16–25% |
Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.
Recent comparable deals
- Merck–Prometheus ($10.8B, MK-7240 TL1A)
- Sanofi–Provention ($2.9B)
- Roche–Telavant ($7.1B TL1A program)
Why Immunology is priced this way
TL1A, IL-23, S1P modulators, and JAK inhibitors dominate recent immunology dealmaking. Big pharma is paying premiums for differentiated MoAs ahead of Humira biosimilar erosion.
Try it live
Run a Immunology deal scenario
Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.
Quick Benchmark
Live data from 1,900+ deals. Select your parameters:
Immunology licensing — frequently asked
What is the median upfront payment for a Immunology licensing deal?
How are Immunology deal milestones structured?
What royalty rates are typical for Immunology licensing?
Is there a free Immunology deal calculator?
How does Immunology licensing compare to other therapeutic areas?
7-Day Free Trial · No Promo Code
Run unlimited immunology deals — Pro.
Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.
Then $299/month · No charge during trial · Cancel anytime